Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT)
$2.38
+0.0050 ( +0.21% ) 2.8K
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Market Data
Open
$2.38
Previous close
$2.37
Volume
2.8K
Market cap
$5.33M
Day range
$2.37 - $2.41
52 week range
$1.58 - $6.15
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | May 20, 2024 |
8-k | 8K-related | 16 | May 09, 2024 |
10-q | Quarterly Reports | 58 | May 09, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |
8-k | 8K-related | 16 | Mar 22, 2024 |
10-k | Annual reports | 70 | Mar 19, 2024 |
8-k | 8K-related | 16 | Feb 27, 2024 |
8-k | 8K-related | 21 | Feb 26, 2024 |
8-k | 8K-related | 17 | Jan 30, 2024 |
8-k | 8K-related | 14 | Nov 28, 2023 |